ACTRN12615000560594已完成1 期
A Phase I, Randomised, Open Label Study of the Safety, Tolerability and Pharmacokinetics of Single Sublingual or Oral Dose of GDN-1 in Adult Healthy Volunteers.
Gordagen Pharmaceuticals Pty Ltd0 个研究点目标入组 60 人开始时间: 2015年5月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Subjects who:
- •1.Are adults aged between 18 and 55 years inclusive at the time of consent.
- •2.Have a Body Mass Index (BMI) of greater than or equal to 18.5 and less than or equal to 27kg/m2
- •3.Have voluntarily given written informed consent.
排除标准
- •Subjects who:
- •1.Are female and breastfeeding and/or of reproductive potential with a positive urine beta human chorionic gonadotropin (beta-HCG) pregnancy test at either Screening or the Baseline Visit;
- •2.Are of child bearing potential and are not able or willing to comply with contraceptive requirements for study participation;
- •3.Are taking regular prescription or OTC medications, other than contraception medications within 30 days of the Baseline Visit and are unwilling to abstain from taking these for the duration of the study;
- •4.Received blood or plasma derivatives in the 3 months preceding the first study dosing
- •5.Donated blood in the three months preceding the first study dosing or intend to make blood donation during the study, or within the three months following the study completion
- •6.Volunteers that are unable to comply with the study procedures/schedule including but not limited to being able to fast or consume the standard meals that will be provided.
- •7.Are taking Vitamin E or Vitamin E containing preparations within the last 3 months prior to the Baseline Visit and are unwilling to abstain from taking these for the duration of the study;
- •8.Have a history of or current clinically significant gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine, oncological, immunodeficiency, neurological, metabolic, haematological or autoimmune disorder or other clinically significant medical conditions that in the investigator’s opinion, may increase the risk of participation;
- •9.Have an existing impairment to their alimentary tract (including oral cavity) which may interfere with investigational product administration and absorption;
- •10.Have an impaired sense of taste (self reported);
- •11.Have an active infection;
- •12.Have a history of chronic alcohol or drug abuse in the three-months period prior to Screening;
- •13.Are current smokers, or have a history of smoking within the three months prior to Screening;
- •14.Have a history of adverse reactions to any of the study medications or components;
- •15.Have taken aspirin or other medication which may increase the risk of bleeding within the 2 weeks prior to Baseline;
- •16.Are known to be HIV, hepatitis B or C positive (note, these will not be tested for);
- •17.Have laboratory blood values:
- •a.Haemoglobin <120 grams/litre (g/L) for men and <11.0 g/L for women
- •b.Neutrophil count <1 x 109/L
- •c.Platelet count < 80 x 109/L
- •d.Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN)
- •e.Amylase >1.5 times ULN (unless serum lipase is less than or equal to 1.5 times ULN)
- •f.Subjects with an estimated creatinine clearance of <80 mL/minute (min)
- •g.INR > ULN
- •18. Have received any investigational drug within 30 days prior to the Baseline visit
研究者
相似试验
已完成
1 期
A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)Respiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12618001838202Avalyn Pharma Pty Ltd91
已完成
2 期
A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)NL-OMON50041Avalyn Pharma, Inc.10
进行中（未招募）
1 期
AC220 in adults with refractory/relapsed Acute Myeloid LeukaemiaAcute Myeloid LeukemiaEUCTR2011-005408-13-GBAmbit BioSciences Corporation76
进行中（未招募）
1 期
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)EUCTR2011-005408-13-ITASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.76
未知
1 期
A Phase 1, 2, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinomanresectable Locally Advanced or Metastatic, Medullary Thyroid CarcinomaJPRN-jRCT2080221951AstraZeneca